Projecting the effectiveness of RotaTeq® against rotavirus-related hospitalizations and deaths in six Asian countries

Khoury, Antoine C. El; Mast, T. Christopher; Ciarlet, Max; Markson, Leona E.; Goveia, Michelle G.

doi:10.4161/hv.7.5.14620

Cited by 15 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The model projected an overall effectiveness in the range of 82e89% against RGE-related hospitalizations and a substantial reduction in RGE-related deaths. 104 Merck has received approval for RotaTeq in the United States, and the vaccine was recommended by the Advisory Committee on Immunization Practices (ACIP) for the routine immunization of infants in 2006. 108 Post-marketing surveillance data from the United States have not identified any concern, such as association with intussusceptions or Kawasaki disease, related to the safety of RotaTeq.…”

Section: Human-bovine Rotavirus Reassortant Vaccinementioning

confidence: 99%

Rotavirus infection and the current status of rotavirus vaccines

Chen¹,

Tan²,

Huang

et al. 2012

Journal of the Formosan Medical Association

View full text Add to dashboard Cite

Section: Human-bovine Rotavirus Reassortant Vaccinementioning

confidence: 99%

Rotavirus infection and the current status of rotavirus vaccines

Chen¹,

Tan²,

Huang

et al. 2012

Journal of the Formosan Medical Association

View full text Add to dashboard Cite

“…The effectiveness of the RotaTeq vaccine against rotavirus gastroenteritis-related (RGE) hospitalizations and deaths was tested in Asian countries by Khoury et al . using a simple mathematical model [ 64 ]. Their study showed that the overall effectiveness against RGE-related hospitalizations and the substantial reduction in RGE-related deaths was 82% to 89% in the region.…”

Section: Rotavirus Vaccinesmentioning

confidence: 99%

Disease Caused by Rotavirus Infection

Lin¹,

Chen²,

Liu³

et al. 2014

TOVJ

View full text Add to dashboard Cite

Although rotavirus vaccines are available, rotaviruses remain the major cause of childhood diarrheal disease worldwide. The Rotarix (GlaxoSmithKline Biologicals Rixensart, Belgium) and RotaTeq (Merck and Co., Inc. Whitehouse Station, New Jersey, USA) vaccines are effective for reducing the morbidity and mortality of rotavirus infection. This article aims to assess the epidemiology of rotaviral gastroenteritis and the efficacy and effectiveness of licensed rotavirus vaccines. This review concludes by presenting challenges in the field that require further exploration by and perspectives from basic and translational research in the future.

show abstract

“…[62] However, post-licensure analyses in the USA showed that approximately 1.5 cases of intussusceptions per 100 000 recipients received the fi rst dose of RotaTeq. [63] The effectiveness of RotaTeq vaccine against rotavirus-related hospitalizations and deaths was determined in Asian countries, [64] showing that the overall effectiveness against rotavirus-related hospitalizations and the substantial reduction in rotavirus-related deaths was 82% to 89%.…”

Section: Human-bovine Rotavirus Reassortant Vaccinementioning

confidence: 99%